This is a Validated Antibody Database (VAD) review about Domestic g.. Cdh1, based on 239 published articles (read how Labome selects the articles), using Cdh1 antibody in all methods. It is aimed to help Labome visitors find the most suited Cdh1 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
Cdh1 synonym: cadherin-1; cadherin 1, type 1, E-cadherin (epithelial)
Invitrogen
| mouse monoclonal (HECD-1) |
| In order to study the effect of angiocrine factors on retinal pigment epithelium basement membrane and barrier function, Invitrogen Cdh1 antibody (Thermo Fisher Scientific, 131700) was used in western blot on human samples at 1:1000 (fig 5g). Nat Commun (2017) ncbi |
| mouse monoclonal (HECD-1) |
| In order to test if MUC1 contributes to epithelial tubular cell plasticity and kidney fibrosis, Invitrogen Cdh1 antibody (ThermoFisher, 13-1700) was used in immunohistochemistry on human samples (fig 1c). Biochim Biophys Acta Mol Basis Dis (2017) ncbi |
| mouse monoclonal (HECD-1) |
| In order to suggest that EGFR promotes survival of prostate tumor-initiating cells and circulating tumor cells that metastasize to bone, whereas HER2 supports the growth of prostate cancer cells once they are established at metastatic sites, Invitrogen Cdh1 antibody (ThermoFisher, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:200 and in western blot on human samples (fig 3c). Cancer Res (2017) ncbi |
| mouse monoclonal (HECD-1) |
| In order to generate an iPSC line from a patient with Kleefstra syndrome, Invitrogen Cdh1 antibody (Thermo Fisher, 13-1700) was used in immunohistochemistry on human samples at 1:1000 (fig 1a). Stem Cell Res (2016) ncbi |
| mouse monoclonal (HECD-1) |
| In order to investigate the alternative splicing of E-cadherin mRNA, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunocytochemistry on human samples at 2 ug/ml (fig 4e) and in western blot on human samples (fig 4b). J Cell Physiol (2017) ncbi |
| mouse monoclonal (HECD-1) |
| In order to discuss the defects observed in the neosquamous epithelium after ablation of Barrett's esophagus, Invitrogen Cdh1 antibody (Invitrogen, 13-1700) was used in western blot on human samples (fig 1a). Dig Dis Sci (2016) ncbi |
| mouse monoclonal (HECD-1) |
| In order to develop strategies to assess and characterize sporadic cases of Alzheimer's disease, Invitrogen Cdh1 antibody (Thermo Fisher Scientific, 13-1700) was used in immunocytochemistry on human samples at 1:1000 (fig 1A). Stem Cell Res (2016) ncbi |
| mouse monoclonal (HECD-1) |
| In order to develop methods to study and characterize sporadic cases of Alzheimer's disease, Invitrogen Cdh1 antibody (Thermo Fisher Scientific, 13-1700) was used in immunocytochemistry on human samples at 1:1000 (fig 1A). Stem Cell Res (2016) ncbi |
| mouse monoclonal (HECD-1) |
| In order to present methods to characterize cells from sporadic cases of Alzheimer's disease, Invitrogen Cdh1 antibody (Thermo Fisher Scientific, 13-1700) was used in immunocytochemistry on human samples at 1:1000 (fig 1A). Stem Cell Res (2016) ncbi |
| mouse monoclonal (HECD-1) |
| In order to present a technique to study sporadic cases of Alzheimer's disease, Invitrogen Cdh1 antibody (Thermo Fisher Scientific, 13-1700) was used in immunocytochemistry on human samples at 1:1000 (fig 1A). Stem Cell Res (2016) ncbi |
| mouse monoclonal (HECD-1) |
| In order to assess the promotion of CAR-dependent migration of leukocytes across epithelial monolayers by TNF-alpha, Invitrogen Cdh1 antibody (Invitrogen, HECD-1) was used in western blot on human samples (fig 2). Sci Rep (2016) ncbi |
| mouse monoclonal (HECD-1) |
| In order to elucidate regulation of E-cadherin and CD24 by determination of cell fate transition and impeding tumor initiation and progression in breast cancer via HOXA5, Invitrogen Cdh1 antibody (Invitrogen, 13-1700) was used in immunocytochemistry on human samples (fig 2), in immunohistochemistry on human samples at 1:500 (fig 5) and in western blot on human samples (fig 2). Oncogene (2016) ncbi |
| mouse monoclonal (HECD-1) |
| In order to utilize the model system of primary human hepatocyte spheroids for drug-induced liver injury, disease, and liver function, Invitrogen Cdh1 antibody (Thermo Scientific, 13-1700) was used in immunocytochemistry on human samples at 1:300 (fig 2). Sci Rep (2016) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study expression levels of CA125, CA19-9, CEA, and EpCAM in pseudomyxoma peritonei, Invitrogen Cdh1 antibody (ThermoFisher Scientific, HECD-1) was used in immunohistochemistry - paraffin section on human samples (fig s2). Hum Pathol (2016) ncbi |
| mouse monoclonal (HECD-1) |
| In order to characterize the functional and prognostic importance of MAP4K5 in pancreatic cancer, Invitrogen Cdh1 antibody (Life Tech, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:7000 (fig 2) and in western blot on human samples (fig 4). PLoS ONE (2016) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study a decrease in expression of miR-205 in inflammatory breast cancer due to MicroRNA expression profiling, Invitrogen Cdh1 antibody (Life Technologies, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:7000 (fig 7). Mod Pathol (2016) ncbi |
| mouse monoclonal (HECD-1) |
| In order to assess the induction of epithelial-to-mesenchymal transition and the increase in invasiveness in rectal cancer due to therapy-induced cellular senescence, Invitrogen Cdh1 antibody (Life Technologies, HECD-1) was used in immunocytochemistry on human samples at 1:1000 (fig 4). Clin Colorectal Cancer (2016) ncbi |
| mouse monoclonal (HECD-1) |
| In order to test if lysophosphatidic acid stimulates uPAR expression and activity in ovarian epithelial cancer cells, Invitrogen Cdh1 antibody (Invitrogen, HECD-1) was used in immunocytochemistry on human samples . Anticancer Res (2015) ncbi |
| mouse monoclonal (HECD-1) |
| In order to investigate the role of LZTFL1 in lung oncogenesis, Invitrogen Cdh1 antibody (Life Technologies, 13-1700) was used in western blot on mouse samples . Oncogene (2016) ncbi |
| mouse monoclonal (HECD-1) |
| In order to assess the safety and efficacy of selumetinib on pancreatic ductal adenocarcinoma, Invitrogen Cdh1 antibody (Invitrogen, 13-1700) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig 3). Clin Cancer Res (2016) ncbi |
| mouse monoclonal (HECD-1) |
| In order to assess the involvement of lysophosphatidic acid in epithelial ovarian carcinoma, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunocytochemistry on human samples . J Biol Chem (2015) ncbi |
| mouse monoclonal (HECD-1) |
| In order to discuss the role and regulation of cell-cell adhesion in prostate cancer aggressiveness, Invitrogen Cdh1 antibody (Invitrogen, HECD-1) was used in western blot on mouse samples . Cancer Med (2015) ncbi |
| mouse monoclonal (HECD-1) |
| In order to analyze breast cancer subtypes and retrospective analysis of metastatic behaviour, Invitrogen Cdh1 antibody (Invitrogen, HECD-1) was used in immunohistochemistry - paraffin section on human samples (tbl 2). Breast Cancer Res Treat (2015) ncbi |
| mouse monoclonal (HECD-1) |
| In order to examine Notch localization and activation in non-small cell lung cancer, Invitrogen Cdh1 antibody (Invitrogen, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:100 and in western blot on human samples at 1:500. J Hematol Oncol (2015) ncbi |
| mouse monoclonal (HECD-1) |
| In order to investigate the expression and role of HYAL1 and HYAL2 in normal tissues, precancerous endometrial tissues, and endometrial carcinomas, Invitrogen Cdh1 antibody (Invitrogen, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 1). Gynecol Oncol (2015) ncbi |
| mouse monoclonal (HECD-1) |
| Invitrogen Cdh1 antibody (Zymed Laboratories, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:3000. Hum Pathol (2015) ncbi |
| mouse monoclonal (HECD-1) |
| In order to determine the localization of NLRP7 and KHDC3L in human oocytes and preimplantation embryos, Invitrogen Cdh1 antibody (Invitrogen, 13-1700) was used in immunocytochemistry on human samples at 1:100 (fig 4). Hum Reprod (2015) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study the effect of HNF4alpha on the chemosensitivity to oxaliplatin and 5-FU in renal cell carcinoma, Invitrogen Cdh1 antibody (Life Technologies, 13-1700) was used in immunocytochemistry on human samples . J Pharm Sci (2014) ncbi |
| mouse monoclonal (HECD-1) |
| In order to generate and assess primary pancreatic adenocarcinoma cell lines for colony forming capacity, tumourigenicity, expression of known cancer cell surface markers and cancer stem-like characteristics, Invitrogen Cdh1 antibody (Invitrogen, 13-1700) was used in immunohistochemistry on human samples at 1:3000. PLoS ONE (2014) ncbi |
| mouse monoclonal (HECD-1) |
| In order to analyze LRIG3 expression through immunohistochemical studies in cervical intraepithelial neoplasia and invasive squamous cell cervical cancer and the association with tumor markers, hormones, high-risk HPV infection, smoking, and patient outcome, Invitrogen Cdh1 antibody (Zymed, 13-1700) was used in immunohistochemistry - paraffin section on human samples at 1:2500 (tbl 3). Eur J Histochem (2014) ncbi |
| mouse monoclonal (HECD-1) |
| Invitrogen Cdh1 antibody (Zymed Laboratories, HECD-1) was used in immunohistochemistry on mouse samples . Head Neck (2015) ncbi |
| mouse monoclonal (HECD-1) |
| In order to identify serines in the beta-catenin-binding domain of E-cadherin that are phosphorylated, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in western blot on human samples (fig 3). Mol Biol Cell (2014) ncbi |
| mouse monoclonal (HECD-1) |
| In order to investigate the effect of glycosylation on tumor cell adhesion and invasion and its mechanism, Invitrogen Cdh1 antibody (Zymed Labs, HECD-1) was used in flow cytometry on human samples at 1:50. PLoS ONE (2014) ncbi |
| mouse monoclonal (HECD-1) |
| Invitrogen Cdh1 antibody (Zymed Laboratories Inc, HECD-1) was used in immunohistochemistry - paraffin section on mouse samples . Clin Cancer Res (2014) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study the localization of Helicobacter pylori on the apical surface of gastrointestinal epithelium and its damaging effect on the mucosal barrier, Invitrogen Cdh1 antibody (Invitrogen, HECD-1) was used in immunocytochemistry on human samples and in western blot on human samples . Helicobacter (2014) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study the release of soluble giant cadherin Fat1 from pancreatic cancer cells, Invitrogen Cdh1 antibody (Invitrogen, 13-1700) was used in western blot on human samples . PLoS ONE (2014) ncbi |
| mouse monoclonal (HECD-1) |
| Invitrogen Cdh1 antibody (Zymed Laboratories, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:2000. Hum Pathol (2014) ncbi |
| mouse monoclonal (HECD-1) |
| In order to explore interactions between human tumor cells and a humanized bone microenvironment, Invitrogen Cdh1 antibody (Invitrogen, 13-1700) was used in immunohistochemistry on human samples at 1:100 (fig 7). Clin Exp Metastasis (2014) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study the efficacy and tolerability of the irreversible tyrosine kinase inhibitor dacomitinib in human bladder cancer models, Invitrogen Cdh1 antibody (Zymed, 13-1700) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 5). Mol Med (2013) ncbi |
| mouse monoclonal (HECD-1) |
| In order to describe the magnetic levitation method of 3D cell culturing, Invitrogen Cdh1 antibody (Invitrogen, 13-1700) was used in immunohistochemistry on human samples at 1:200 (fig 9). Nat Protoc (2013) ncbi |
| mouse monoclonal (HECD-1) |
| In order to elucidate the role of Snail in pancreatic cancer development, Invitrogen Cdh1 antibody (Life Technologies, 13-1700) was used in western blot on mouse samples (fig 1). Mol Cancer Res (2013) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study listeriosis in wild-type mice using InlA that has been "murinized" to interact with mouse Ecad, Invitrogen Cdh1 antibody (Invitrogen, clone HECD-1) was used in western blot on mouse samples (fig 2). PLoS Pathog (2013) ncbi |
| mouse monoclonal (HECD-1) |
| In order to test if EMT-related proteins alterations are associated with the clinicopathological features and prognosis in lung adenocarcinoma, Invitrogen Cdh1 antibody (Zymed, clone HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 1). Diagn Pathol (2013) ncbi |
| mouse monoclonal (HECD-1) |
| In order to examine E-cadherin-negative ductal carcinoma, Invitrogen Cdh1 antibody (Zymed, 13-1700) was used in immunohistochemistry on human samples at 1:100 (fig 1). Histopathology (2013) ncbi |
| mouse monoclonal (HECD-1) |
| In order to identify new genes involved in gastric cancer, Invitrogen Cdh1 antibody (Invitrogen, clone HECD-1) was used in immunohistochemistry - paraffin section on human samples (fig 3). J Pathol (2013) ncbi |
| mouse monoclonal (HECD-1) |
| In order to assess if the EphA2/ephrin-A1 signaling axis is altered in psoriasis, Invitrogen Cdh1 antibody (Invitrogen, HECD-1) was used in western blot on human samples (fig 1). J Invest Dermatol (2013) ncbi |
| mouse monoclonal (HECD-1) |
| In order to compare the invasiveness of a collection of colorectal cancer cell lines with varying RhoA, Rac1, and Cdc42 activities, Invitrogen Cdh1 antibody (ZYMED, HECD1) was used in immunocytochemistry on human samples at 1:200 (fig 4). PLoS ONE (2012) ncbi |
| mouse monoclonal (HECD-1) |
| In order to discuss methods to identify yessotoxin, Invitrogen Cdh1 antibody (Zymed, clone HECD-1) was used in western blot on human samples at 2 ug/ml. Chemosphere (2013) ncbi |
| mouse monoclonal (HECD-1) |
| In order to characterise novel sinonasal undifferentiated carcinoma cell lines, Invitrogen Cdh1 antibody (Invitrogen, HECD-1) was used in immunohistochemistry on human samples (fig s3). Clin Cancer Res (2012) ncbi |
| mouse monoclonal (HECD-1) |
| In order to report that lethal toxin targets alveolar epithelial cells, Invitrogen Cdh1 antibody (Invitrogen, HECD-1) was used in immunocytochemistry on human samples (fig 4). Infect Immun (2012) ncbi |
| mouse monoclonal (HECD-1) |
| In order to evaluate the effectiveness of VEGF restriction on orthotopic tumor growth and elucidate the mechanism of treatment resistance, Invitrogen Cdh1 antibody (Invitrogen, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 6). Neuro Oncol (2012) ncbi |
| mouse monoclonal (HECD-1) |
| In order to examine the effects of rapamycin treatment using an organotypic culture of human skin explants, Invitrogen Cdh1 antibody (Invitrogen, 13-1700) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 4). Arch Dermatol Res (2013) ncbi |
| mouse monoclonal (HECD-1) |
| In order to identify molecular alterations that contribute to the development of pulmonary carcinoids, Invitrogen Cdh1 antibody (Zymed Laboratories, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig 1). Int J Oncol (2012) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study the expression and localization of E-cadherin in canine round cell tumors, Invitrogen Cdh1 antibody (Invitrogen, HECD-1) was used in immunohistochemistry - paraffin section on dog samples (fig 2). Vet J (2012) ncbi |
| mouse monoclonal (HECD-1) |
| In order to examine distribution of the GCTM-5 antigen in normal tissues and disease states and characterize the antigen biochemically, Invitrogen Cdh1 antibody (Invitrogen, HECD-1) was used in immunocytochemistry on human samples (fig 4). Stem Cells (2012) ncbi |
| mouse monoclonal (HECD-1) |
| In order to correlate the of CADM4, E-cadherin, and Ki-67 in colorectal adenocarcinomas, Invitrogen Cdh1 antibody (Zymed, 13-1700) was used in immunohistochemistry - paraffin section on human samples at 1:200 (tbl 1). J Clin Pathol (2012) ncbi |
| mouse monoclonal (HECD-1) |
| In order to develop and characterize a model for Hailey-Hailey disease using normal keratinocytes, Invitrogen Cdh1 antibody (Invitrogen, 13-1700) was used in immunocytochemistry on human samples (fig 4) and in western blot on human samples (fig 2). Exp Dermatol (2012) ncbi |
| mouse monoclonal (HECD-1) |
| In order to investigate the effect of lysophosphatidic acid on E-cadherin junctional integrity, Invitrogen Cdh1 antibody (Zymed, hecd-1) was used in immunocytochemistry on human samples (fig 1). J Oncol (2012) ncbi |
| mouse monoclonal (HECD-1) |
| In order to develop and characterize a new 3-D spheroid cell culture system that mimics solid tumors, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunocytochemistry on human samples at 1:2500 (tbl 1). Exp Cell Res (2012) ncbi |
| mouse monoclonal (HECD-1) |
| In order to test if destabilization accounts for the pathogenicity of E-cadherin missense mutations in hereditary diffuse gastric cancer, Invitrogen Cdh1 antibody (Zymed Laboratories, HECD1) was used in flow cytometry on mouse samples at 1:100. PLoS ONE (2012) ncbi |
| mouse monoclonal (HECD-1) |
| In order to investigate the involvement of the tumor microenvironment in the epigenetic control of genes critical to cancer progression, Invitrogen Cdh1 antibody (Invitrogen, 13-1700) was used in immunocytochemistry on human samples (fig 1). Epigenetics (2012) ncbi |
| mouse monoclonal (HECD-1) |
| In order to establish and characterize a three-dimensional organotypic model of the human airway mucosa, Invitrogen Cdh1 antibody (Invitrogen, HECD-1) was used in immunohistochemistry - frozen section on human samples (fig 3). Am J Physiol Lung Cell Mol Physiol (2012) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study the effect of contraceptive choices on cervical intraepithelial neoplasia, Invitrogen Cdh1 antibody (Zymed, 13-1700) was used in immunohistochemistry - paraffin section on human samples at 1:2500 (tbl 3). Contraception (2012) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study the EGF-induced, ADAM10-dependent shedding of E-cadherin by prostate epithelial cells, Invitrogen Cdh1 antibody (Invitrogen, clone HECD-1) was used in western blot on human samples (fig 1). Cell Signal (2012) ncbi |
| mouse monoclonal (HECD-1) |
| In order to test if CDH11 is increased in pulmonary fibrosis and contributes its development, Invitrogen Cdh1 antibody (Invitrogen, HECD-1) was used in immunocytochemistry on mouse samples (fig 5). FASEB J (2012) ncbi |
| mouse monoclonal (HECD-1) |
| In order to investigate how Listeria monocytogenes crosses the epithelium, Invitrogen Cdh1 antibody (Invitrogen, HECD-1) was used in immunohistochemistry on mouse samples (fig 1). J Exp Med (2011) ncbi |
| mouse monoclonal (HECD-1) |
| In order to test in endothelial cells contribute to the epithelial to mesenchymal transition, Invitrogen Cdh1 antibody (Zymed, 13-1700) was used in immunohistochemistry - paraffin section on human samples (fig 6) and in western blot on human samples at 1:500 (fig 3). PLoS ONE (2011) ncbi |
| mouse monoclonal (HECD-1) |
| In order to identify cell surface protein biomarkers that discriminate between low-risk adenomas and normal colons from high-risk adenomas and colorectal cancer, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in western blot on human samples at 1:1000 (fig 1). Gut (2012) ncbi |
| mouse monoclonal (HECD-1) |
| In order to discuss immunohistochemical analysis of the olfactory epithelium, Invitrogen Cdh1 antibody (Invitrogen, 13-1700) was used in immunohistochemistry - frozen section on human samples at 1:300 (tbl 1). Laryngoscope (2011) ncbi |
| mouse monoclonal (HECD-1) |
| In order to discuss the contribution of epithelial-to-mesenchymal transition to invasive and metastatic carcinomas, Invitrogen Cdh1 antibody (Invitrogen, HECD-1) was used in immunocytochemistry on human samples (fig 2). Mol Cancer (2011) ncbi |
| mouse monoclonal (HECD-1) |
| In order to investigate the interactions among LRIG1, LRIG2, and other cancer markers as diagnostics in CIN, Invitrogen Cdh1 antibody (Zymed, 13-1700) was used in immunohistochemistry - paraffin section on human samples at 1:2500 (tbl 1). Gynecol Oncol (2011) ncbi |
| mouse monoclonal (HECD-1) |
| In order to examine barrier function in the esophageal epithelium of patients with gastroesophageal reflux disease, Invitrogen Cdh1 antibody (Zymed, 13-1700) was used in immunohistochemistry on human samples (fig 4). Am J Gastroenterol (2011) ncbi |
| mouse monoclonal (HECD-1) |
| In order to use the SW620 secretome to identify novel biomarker candidates, Invitrogen Cdh1 antibody (Zymed, 13-1700) was used in western blot on human samples at 1:1000 (fig 5). Proteomics Clin Appl (2007) ncbi |
| mouse monoclonal (HECD-1) |
| In order to establish and characterize an epithelial cell line derived from a breast carcinoma from a patient with a strong family history of breast cancer but no known breast cancer susceptibility mutation, Invitrogen Cdh1 antibody (Zymed, HECD1) was used in immunocytochemistry on human samples (tbl 1). In Vitro Cell Dev Biol Anim (2011) ncbi |
| mouse monoclonal (HECD-1) |
| In order to investigate how trafficking of E-cadherin contributes to breast cancer, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunocytochemistry on human samples (fig 1) and in immunohistochemistry on human samples (fig 1). Anticancer Res (2010) ncbi |
| mouse monoclonal (HECD-1) |
| In order to investigate E-cadherin expression in morphologically typical invasive lobular carcinomas, Invitrogen Cdh1 antibody (Zymed, 13-1700) was used in immunohistochemistry on human samples at 1:200 (fig 1). Am J Surg Pathol (2010) ncbi |
| mouse monoclonal (HECD-1) |
| In order to use a novel 3D culture system to assess cell-matrix interactions that contribute to carcinogenesis, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunocytochemistry on human samples at 1:200 (fig s1). Biomaterials (2010) ncbi |
| mouse monoclonal (HECD-1) |
| In order to report that membrane type 1-matrix metalloproteinase cleaves the extracellular matrix and causes cellular aggregation of keratinocytes and squamous cell carcinoma cells, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in western blot on human samples (fig 4). J Biol Chem (2010) ncbi |
| mouse monoclonal (HECD-1) |
| In order to develop an in vitro model for experimental studies of cancer cell invasion, Invitrogen Cdh1 antibody (Zymed, 13-1700) was used in immunohistochemistry on human samples at 0.2 ug/ul (fig 1). Eur J Oral Sci (2010) ncbi |
| mouse monoclonal (HECD-1) |
| In order to investigate protein modification of beta-catenin, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in western blot on human samples (fig 3). PLoS ONE (2010) ncbi |
| mouse monoclonal (HECD-1) |
| In order to elucidate the function of alpha3beta1 integrin, Invitrogen Cdh1 antibody (Invitrogen, 13-1700) was used in western blot on human samples (fig 6). Wound Repair Regen (2010) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study barrier integrity and tight junction protein expression using in vitro lung epithelial barrier model, Invitrogen Cdh1 antibody (Invitrogen, HECD-1) was used in immunocytochemistry on human samples (fig 7). Immunobiology (2011) ncbi |
| mouse monoclonal (HECD-1) |
| In order to characterize the expression of a number of proteins in tissues from pseudomyxoma peritonei patients, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry on human samples at 1:100 (tbl 1). Hum Pathol (2010) ncbi |
| mouse monoclonal (HECD-1) |
| In order to examine the effect of uPAR modulation on oral squamous cell carcinoma, Invitrogen Cdh1 antibody (Zymed, 13-1700) was used in flow cytometry on human samples at 1:100. Mol Cancer Res (2010) ncbi |
| mouse monoclonal (HECD-1) |
| In order to measure the expression of tenascin-C, osteopontin, and fibronectin in inflammatory myofibroblastic tumor of the lung, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:300 (tbl 2). APMIS (2010) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study tissue tumor marker expression in smokers with cervical intraepithelial neoplasia or normal squamous cervical epithelium, Invitrogen Cdh1 antibody (Zymed, 13-1700) was used in immunohistochemistry - paraffin section on human samples at 1:2500 (tbl 1). Am J Obstet Gynecol (2010) ncbi |
| mouse monoclonal (HECD-1) |
| In order to discuss the effects of E-cadherin overexpression in highly malignant inflammatory breast cancer, Invitrogen Cdh1 antibody (Invitrogen, HECD-1) was used in blocking or activating experiments on human samples . BMC Cancer (2009) ncbi |
| mouse monoclonal (HECD-1) |
| In order to test if intercellular adhesion affects beta-catenin signaling, Invitrogen Cdh1 antibody (Invitrogen, HECD-1) was used in immunohistochemistry - frozen section on human samples (fig 2) and in western blot on human samples (fig 1). J Cell Biol (2009) ncbi |
| mouse monoclonal (HECD-1) |
| In order to elucidate the relationship between contact inhibition of growth and growth factors, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunocytochemistry on human samples . Proc Natl Acad Sci U S A (2009) ncbi |
| mouse monoclonal (HECD-1) |
| In order to develop a new evanescent-wave fluorescence excitation method for biological samples, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunocytochemistry on human samples (fig 4a). Opt Express (2009) ncbi |
| mouse monoclonal (HECD-1) |
| In order to explore the functional implication of different cadherins in breast cancer biology, Invitrogen Cdh1 antibody (Zymed, HECD1) was used in immunocytochemistry on human samples (fig 1b). BMC Cancer (2009) ncbi |
| mouse monoclonal (HECD-1) |
| In order to assess the sensitivity of 18 squamous cell carcinoma of the head and neck cell lines to gefitinib, Invitrogen Cdh1 antibody (Zymed, 13-1700) was used in western blot on human samples (fig 2). J Pathol (2009) ncbi |
| mouse monoclonal (HECD-1) |
| In order to discuss markers to diagnosis of diabetic nephropathy, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 5) and in western blot on human samples at 1:1000 (fig 3). Diabetes Metab Res Rev (2009) ncbi |
| mouse monoclonal (HECD-1) |
| In order to examine the effects of connexin-43 expression in breast cancer cells, Invitrogen Cdh1 antibody (Zymed, 13-1700) was used in western blot on human samples . Clin Exp Metastasis (2008) ncbi |
| mouse monoclonal (HECD-1) |
| In order to ascertain the role of epithelial cadherin in gamete interaction, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunocytochemistry on human samples at 20 ug/ml (fig 4) and in western blot on human samples (fig 3). Mol Hum Reprod (2008) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study Rac-dependent cyclin D1 expression, Invitrogen Cdh1 antibody (Zymed Laboratories, 13-1700) was used in immunocytochemistry on human samples and in western blot on human samples . J Biol Chem (2008) ncbi |
| mouse monoclonal (HECD-1) |
| In order to use mass spectroscopy to identify proteins that contribute to adhesion of human embryonic stem cells, Invitrogen Cdh1 antibody (Zymed Laboratories, HECD-1) was used in immunocytochemistry on human samples at 1:200. Stem Cells (2008) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study the role of the E7 oncogene in restoring E-cadherin expression in human papillomavirus 16-transformed keratinocytes, Invitrogen Cdh1 antibody (Zymed Laboratories, HECD-1) was used in immunohistochemistry - paraffin section on human samples , in flow cytometry on human samples at 1:200 and in western blot on human samples at 1:2000. Carcinogenesis (2008) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study the genomic and immunophenotypical features of pure invasive micropapillary carcinomas, Invitrogen Cdh1 antibody (Zymed, clone HECD-1) was used in immunohistochemistry on human samples at 1:200 (tbl 2). J Pathol (2008) ncbi |
| mouse monoclonal (HECD-1) |
| In order to examine the role of E-cadherin and ADAM15 in ErbB receptor signaling, Invitrogen Cdh1 antibody (Zymed Laboratories, HECD-1) was used in immunoprecipitation on human samples and in western blot on human samples . J Biol Chem (2008) ncbi |
| mouse monoclonal (HECD-1) |
| In order to examine the expression and localization of the BRCA1 protein and assess its prognostic value in breast carcinomas, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:100. Hum Pathol (2008) ncbi |
| mouse monoclonal (HECD-1) |
| In order to examine cadherin expression in mouse fibroblast-like synoviocytes, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in western blot on human samples (fig 3c). Arthritis Rheum (2008) ncbi |
| mouse monoclonal (HECD-1) |
| In order to identify key matrix components required for ex vivo maintenance of human hepatic progenitors, Invitrogen Cdh1 antibody (ZYMED, 13-1700) was used in immunohistochemistry on human samples (tbl 2). Tissue Eng Part A (2008) ncbi |
| mouse monoclonal (HECD-1) |
| In order to test if heat shock proteins interact functionally with the cadherin-catenin cell adhesion system in breast cancer, Invitrogen Cdh1 antibody (Zymed, 13-1700) was used in immunohistochemistry - paraffin section on human samples at 1:20 (fig 1a) and in western blot on human samples (fig 3a). Cell Stress Chaperones (2008) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study adhesion molecules responsible for rBM-driven versus spontaneous spheroid formation in breast tumor cell lines relevant for antitumor drug testing, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in flow cytometry on human samples at 2.5 ug/ml. Int J Oncol (2007) ncbi |
| mouse monoclonal (HECD-1) |
| In order to identify and characterize a new type of adherens junction in human meningiomas, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunocytochemistry on human samples (fig 4) and in western blot on human samples (fig 6). Cell Tissue Res (2008) ncbi |
| mouse monoclonal (HECD-1) |
| In order to assess whether E-cadherin-dependent cell-cell contact mediates CaSki cell apoptosis during multicellular tumor spheroid formation, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in blocking or activating experiments on human samples and in western blot on human samples at 1:1000. Apoptosis (2008) ncbi |
| mouse monoclonal (HECD-1) |
| In order to postulate a role for extracellular matrix-integrin regulation of the Rac1-c-jun-N-terminal kinase pathway in estrogen-regulated proliferation in estrogen receptor positive breast cancer cells, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in western blot on human samples at 1:5000. Breast Cancer Res Treat (2008) ncbi |
| mouse monoclonal (HECD-1) |
| In order to determine interaction affinities of E-cadherin dimers on both cell surfaces and agarose beads, Invitrogen Cdh1 antibody (Zymed Laboratories, HECD-1) was used in immunocytochemistry on human samples (fig 5). Mol Biol Cell (2007) ncbi |
| mouse monoclonal (HECD-1) |
| In order to assess the clinical significance of E-cadherin and p120ctn expression in esophageal squamous cell carcinoma, Invitrogen Cdh1 antibody (Zymed Laboratories, 13-1700) was used in immunohistochemistry - paraffin section on human samples at 1:200. Ann Surg Oncol (2007) ncbi |
| mouse monoclonal (HECD-1) |
| In order to assess the use of E-cadherin and beta-catenin as markers of nodal metastasis in oral squamous cell carcinoma, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples (fig 1). Oral Dis (2007) ncbi |
| mouse monoclonal (HECD-1) |
| In order to quantify the expression of E-cadherin and a- and b-catenins that form the cadherin-catenin complex in tumoral vascular invasion in metastatic sentinel lymph node patients, Invitrogen Cdh1 antibody (Zymed, ECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 1). Pathol Res Pract (2007) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study the effects of matrix-induced integrin clustering on proteinase-catalyzed E-cadherin ectodomain shedding and identify a role for MMP-9, Invitrogen Cdh1 antibody (Invitrogen, HECD-1) was used in western blot on human samples at 1:4000 (fig 1). Cancer Res (2007) ncbi |
| mouse monoclonal (HECD-1) |
| In order to demonstrate that the RhoA pathway mediates COX-2 signaling and alters the formation of adherens junctions to increase cell motility, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunocytochemistry on human samples . Cancer Res (2006) ncbi |
| mouse monoclonal (HECD-1) |
| In order to discuss therapy options for triple-negative breast cancer, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry on human samples at 1:100 (tbl 1). Cancer (2007) ncbi |
| mouse monoclonal (HECD-1) |
| In order to report the methylation profile of CpG islands in cutaneous squamous cell carcinomas, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry on human samples (fig 2h). Br J Dermatol (2006) ncbi |
| mouse monoclonal (HECD-1) |
| In order to measure CDH1 mRNA and protein in a series of normal and neoplastic testes, Invitrogen Cdh1 antibody (Zymed, 13-1700) was used in immunohistochemistry on human samples at 1:100, in ELISA on human samples and in western blot on human samples at 1:500. APMIS (2006) ncbi |
| mouse monoclonal (HECD-1) |
| In order to investigate the role of secreted protein acidic and rich in cysteine in primary tumor development, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunocytochemistry on human samples . Cancer Res (2006) ncbi |
| mouse monoclonal (HECD-1) |
| In order to examine the first family diagnosed with hereditary diffuse gastric cancer in Spain for mutations in the E-cadherin gene, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples . Eur J Surg Oncol (2006) ncbi |
| mouse monoclonal (HECD-1) |
| In order to discuss the consequences of CDH1 germline mutations in the general population and in patients with hereditary diffuse gastric cancer, Invitrogen Cdh1 antibody (Zymed, HECD?\1) was used in immunocytochemistry on human samples (fig 6) and in immunohistochemistry on human samples (fig 1). J Med Genet (2006) ncbi |
| mouse monoclonal (HECD-1) |
| In order to clarify how PI3KC2beta regulates the migration and survival of human tumor cells, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunocytochemistry on human samples at 20 ug/ml (fig 5). Mol Biol Cell (2006) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study E-cadherin dimer assembly, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunoprecipitation on human samples (fig 5) and in immunocytochemistry on human samples (fig 4). Mol Biol Cell (2006) ncbi |
| mouse monoclonal (HECD-1) |
| In order to discuss assays to study the effects of Rap1 on cadherin-dependent adhesion in epithelia, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunocytochemistry on hamsters samples (fig 2), in western blot on hamsters samples (fig 2) and in immunocytochemistry on human samples (fig 1). Methods Enzymol (2006) ncbi |
| mouse monoclonal (HECD-1) |
| In order to discuss how H-ras contributes to the transformation of human mammary epithelial cells, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:300. Cancer Cell Int (2006) ncbi |
| mouse monoclonal (HECD-1) |
| In order to discover if N-cadherin expression is associated with the bladder tumor progression, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:600. Clin Cancer Res (2006) ncbi |
| mouse monoclonal (HECD-1) |
| In order to assess the relationship between E-cadherin status and gene expression levels in human mammary cell lines, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in western blot on human samples at 1:1000 (fig 1). Br J Cancer (2006) ncbi |
| mouse monoclonal (HECD-1) |
| In order to clarify the prognostic role of E-cadherin and beta- and gamma-catenins and discuss their relationship to CD44 in epithelial ovarian carcinoma, Invitrogen Cdh1 antibody (Zymed, HECD?\1) was used in immunohistochemistry - paraffin section on human samples at 1:100 (tbl 2). J Clin Pathol (2006) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study the morphological and immunophenotypic features of breast carcinomas with basal and myoepithelial differentiation, Invitrogen Cdh1 antibody (Zymed Laboratories, clone ZHECD-1) was used in immunohistochemistry on human samples at 1:100 (tbl 7). J Pathol (2006) ncbi |
| mouse monoclonal (HECD-1) |
| In order to assess E-cadherin expression in mammary lobular carcinomas and ductal carcinomas, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:400 (fig 1). World J Surg Oncol (2005) ncbi |
| mouse monoclonal (HECD-1) |
| In order to investigate the mechanism of copper-induced internalization of cellular prion protein in neuronal cells, Invitrogen Cdh1 antibody (Zymed, 13-1700) was used in immunocytochemistry on human samples at 1:200 (fig 4B) and in western blot on human samples at 1:1000 (fig 3B). J Cell Sci (2005) ncbi |
| mouse monoclonal (HECD-1) |
| In order to investigate the relationship between hepatocyte growth factor and E-cadherin in gastric carcinoma, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples (fig 1C), in immunocytochemistry on human samples (fig 4Ac) and in western blot on human samples (fig 3B). Ann Surg (2005) ncbi |
| mouse monoclonal (HECD-1) |
| In order to report on three cases of polymorphous adenocarcinoma of the breast, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:1000. Virchows Arch (2006) ncbi |
| mouse monoclonal (HECD-1) |
| In order to examine the roles of hK4 and prostate-specific antigen in the progression of prostate cancer, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunocytochemistry on human samples (fig 5). Endocr Relat Cancer (2005) ncbi |
| mouse monoclonal (HECD-1) |
| In order to test if SLUG activation contributes to the Ras-induced loss of E-cadherin, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunocytochemistry on human samples at 1:400, in western blot on human samples at 1:1000 and in western blot on rat samples at 1:1000. Surgery (2005) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study how abrogation of E-cadherin-mediated adhesion modifies the behavior and phenotype of squamous cell carcinoma, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry on human samples (fig 2). Int J Cancer (2006) ncbi |
| mouse monoclonal (HECD-1) |
| In order to show a functional role of MAPK activation in the motility and invasion of placental site trophoblastic tumors, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in western blot on human samples (fig 2). Am J Pathol (2005) ncbi |
| mouse monoclonal (HECD-1) |
| In order to compare clinicopathological characteristics and immunohistochemical profiles of simultaneous bilateral breast cancer and corresponding lymph node metastases, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:1000. Histol Histopathol (2005) ncbi |
| mouse monoclonal (HECD-1) |
| In order to assess the clinicopathological and prognostic value of E-cadherin in non-lobular types of breast carcinoma, Invitrogen Cdh1 antibody (Zymed, 13-1700) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 1). Histopathology (2005) ncbi |
| mouse monoclonal (HECD-1) |
| In order to describe the features of the epithelial-mesenchymal transition in renal transplants that developed tubular atrophy and interstitial fibrosis, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples (fig 1). Am J Transplant (2005) ncbi |
| mouse monoclonal (HECD-1) |
| In order to assess the use of an 80 kDa fragment of the cell adhesion molecule e-cadherin as a serum biomarker for prostate cancer, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in ELISA on human samples (fig 1). Br J Cancer (2005) ncbi |
| mouse monoclonal (HECD-1) |
| In order to discuss revising the classification systems for breast cancer, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry on human samples at 1:10-1:20. Int J Cancer (2005) ncbi |
| mouse monoclonal (HECD-1) |
| In order to determine CD44s, CD44v6, and E-cadherin expression in primary tumors and metastases, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:300 (fig 1). Oncol Rep (2005) ncbi |
| mouse monoclonal (HECD-1) |
| In order to elucidate the mechanisms of actin reorganization that drive the establishment of apical junctional complex, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunocytochemistry on human samples . Mol Biol Cell (2005) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study the role of E-cadherin/beta-catenin dysregulation in pulmonary neuroendocrine tumors, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:400 (tbl 2). Cancer (2005) ncbi |
| mouse monoclonal (HECD-1) |
| In order to test if immunohistochemical staining for oestrogen receptor alpha, progesterone receptor, and E-cadherin distinguishes metastatic breast carcinoma from primary gastric carcinoma, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry on human samples at 1:1000 (fig 1). Histopathology (2005) ncbi |
| mouse monoclonal (HECD-1) |
| In order to develop and characterize a triple co-culture model of the human airway barrier, Invitrogen Cdh1 antibody (Zymed, 13-1,700) was used in immunocytochemistry on human samples at 1:300 (fig 3). Am J Respir Cell Mol Biol (2005) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study 16q22.1 in breast carcinoma and identify potential tumor suppressor genes, Invitrogen Cdh1 antibody (Zymed, 13-1700) was used in immunohistochemistry - paraffin section on human samples at 1:100 (tbl 1). Int J Cancer (2005) ncbi |
| mouse monoclonal (HECD-1) |
| In order to correlate histologic grade in invasive lobular carcinoma with known prognostic and predictive markers, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples . Mod Pathol (2005) ncbi |
| mouse monoclonal (HECD-1) |
| In order to hypothesize that the E-cad(100) fragment abrogates survival of LNCaP cells following induction of apoptosis, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunocytochemistry on human samples (fig 3) and in western blot on human samples (fig 1). Prostate (2005) ncbi |
| mouse monoclonal (HECD-1) |
| In order to identify biomarkers for accelerated radiotherapy, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:600. Radiother Oncol (2004) ncbi |
| mouse monoclonal (HECD-1) |
| In order to assess the presence and localization of E-cadherin and beta-catenin in normal fetal germ cells and germ cell tumors, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - frozen section on human samples at 1:300 and in immunohistochemistry - paraffin section on human samples at 1:300. J Pathol (2004) ncbi |
| mouse monoclonal (HECD-1) |
| In order to test if overexpression of E-cadherin prevents Ras-induced malignant transformation and suppresses intestinal cell growth, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunocytochemistry on human samples (fig 3) and in western blot on human samples at 1:1000 (fig 1). Surgery (2004) ncbi |
| mouse monoclonal (HECD-1) |
| In order to measure the E- and N-cadherin and beta- and alpha-catenin expression in benign and malignant epithelial neoplasms of the ovary and correlate expression with tumor staging, histological grade, and presence of metastases during evolution, Invitrogen Cdh1 antibody (ZYMED, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:200 (tbl 1). Gynecol Oncol (2004) ncbi |
| mouse monoclonal (HECD-1) |
| In order to test if carcinoma cells form gap junctions with bone cells and assess the function of this interaction, Invitrogen Cdh1 antibody (Zymed, 13-1700) was used in western blot on human samples (fig 4). Int J Cancer (2004) ncbi |
| mouse monoclonal (HECD-1) |
| In order to examine the expression of S100A4 and E-cadherin in a panel of primary and metastatic malignant melanoma and correlate their expression levels to clinicopathological parameters, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:1000. Mod Pathol (2004) ncbi |
| mouse monoclonal (HECD-1) |
| In order to elucidate the relation between the macroscopic growth patterns of gastric carcinoma and the abnormal expression of E-cadherin and alpha- and beta-catenins, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 1). J Clin Gastroenterol (2004) ncbi |
| mouse monoclonal (HECD-1) |
| In order to test if hypermethylation in the CDH1 promoter region correlates with poor prognosis of patients with surgically resected, node-positive, diffuse gastric cancer, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples (fig 2A). Clin Cancer Res (2004) ncbi |
| mouse monoclonal (HECD-1) |
| In order to report on a case of pilomatrix carcinoma with lymph node metastases, Invitrogen Cdh1 antibody (ZYMED, HECD-1) was used in immunohistochemistry on human samples at 1:75 (tbl 2). J Cutan Pathol (2004) ncbi |
| mouse monoclonal (HECD-1) |
| In order to examine E-cadherin gene promoter hypermethylation in gastric carcinomas and its correlation with E-cadherin protein expression, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:100. Ann Oncol (2004) ncbi |
| mouse monoclonal (HECD-1) |
| In order to clarify the role of E-cadherin in prostate cancer progression, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunoprecipitation on human samples (fig 4) and in western blot on human samples at 2.0 ug/ml (fig 2). J Cell Biochem (2004) ncbi |
| mouse monoclonal (HECD-1) |
| In order to examine the role of promoter methylation in regulating E-cadherin expression in oral squamous cell carcinoma, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in western blot on human samples (fig 1). Biochem Biophys Res Commun (2004) ncbi |
| mouse monoclonal (HECD-1) |
| In order to characterize the barrier governing permeability across the junctions of rabbit esophageal epithelium, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on rabbit samples (fig 7). Am J Physiol Gastrointest Liver Physiol (2004) ncbi |
| mouse monoclonal (HECD-1) |
| In order to evaluate an 80 kDa proteolytic fragment of E-cadherin as a potential biomarker for prostate cancer progression and identify proteases responsible for E-cadherin cleavage, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in western blot on human samples . Clin Cancer Res (2003) ncbi |
| mouse monoclonal (HECD-1) |
| In order to test if suppression of Smad3 expression mediates the key oncogenic properties of TGF-beta in gastric cancer, Invitrogen Cdh1 antibody (Zymed, 13?C1700) was used in western blot on human samples . Oncogene (2004) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study how inhibitor of beta-catenin and TCF-4 suppresses beta-catenin function, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in western blot on human samples at 1:10000 (fig 3). Am J Physiol Cell Physiol (2004) ncbi |
| mouse monoclonal (HECD-1) |
| In order to explore cadherin-cadherin interactions, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in western blot on human samples (fig 2). Mol Cell Biol (2003) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study expression of E- and N-cadherin in mesotheliomas and adenocarcinomas, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry on human samples at 1:20 (fig 1). Hum Pathol (2003) ncbi |
| mouse monoclonal (HECD-1) |
| In order to examine E-cadherin inactivation in various types of breast cancer, Invitrogen Cdh1 antibody (Zymed, clone HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 1). Mod Pathol (2003) ncbi |
| mouse monoclonal (HECD-1) |
| In order to report the immunohistochemical and molecular genetic features of the cadherins/catenins complex in thyroid carcinoma, Invitrogen Cdh1 antibody (Zymed, clone HECD-1) was used in immunohistochemistry on human samples at 1:200 (tbl 1). Histopathology (2003) ncbi |
| mouse monoclonal (HECD-1) |
| In order to elucidate the mechanism of matrilysin in repair, Invitrogen Cdh1 antibody (Zymed, HECD-1)) was used in immunocytochemistry on human samples (fig 3a) and in western blot on human samples (fig 3b). Am J Pathol (2003) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study how cell-matrix interactions influence the invasive behavior of a novel, primary peritoneal carcinosarcoma cell line, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in western blot on human samples at 1:1000. Gynecol Oncol (2003) ncbi |
| mouse monoclonal (HECD-1) |
| In order to assess the morphogenetic activities of c-erbB and retinoids on human mammary epithelial cells, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in flow cytometry on human samples (tbl 3), in immunocytochemistry on human samples (fig 5) and in western blot on human samples at 0.5 ug/ml (fig 8). J Cell Physiol (2003) ncbi |
| mouse monoclonal (HECD-1) |
| In order to determine the role of MMP-19 in skin cancer, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples . Int J Cancer (2003) ncbi |
| mouse monoclonal (HECD-1) |
| In order to examine the relationship between paranuclear E-cadherin distribution and the histopathologic characteristics of gastric adenocarcinomas, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples . Am J Clin Pathol (2002) ncbi |
| mouse monoclonal (HECD-1) |
| In order to report that three fibroadenomasfrom one patient simultaneously gave rise to breast carcinoma in situ, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry on human samples . J Clin Pathol (2002) ncbi |
| mouse monoclonal (HECD-1) |
| In order to measure protein expression of adenomatous polyposis coli in primary and metastatic serous ovarian carcinoma, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:2000 (tbl 2). Int J Surg Pathol (2002) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study the existence of novel routes of tumour spread via open channels of pseudoangiomatous stromal hyperplasia, Invitrogen Cdh1 antibody (Zymed, clone HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:1000 (fig 6). Histopathology (2002) ncbi |
| mouse monoclonal (HECD-1) |
| In order to report that activation of the ET-1/ET(B) pathway downregulates E-cadherin in human melanocytes and melanoma cells, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in western blot on human samples . J Clin Invest (2002) ncbi |
| mouse monoclonal (HECD-1) |
| In order to determine the expression pattern and contribution of cell adhesion molecules in adrenal tumors, Invitrogen Cdh1 antibody (Zymed, 13-1700) was used in immunohistochemistry - paraffin section on human samples at 1:1000 (tbl 1) and in western blot on human samples (tbl 3). Endocr Pathol (2002) ncbi |
| mouse monoclonal (HECD-1) |
| In order to optimize E-cadherin immunostaining in paraffin sections to detect variants of ductal infiltrating breast cancer, Invitrogen Cdh1 antibody (Zymed Labs, HECD-1) was used in immunohistochemistry - paraffin section on human samples (fig 3). Histopathology (2002) ncbi |
| mouse monoclonal (HECD-1) |
| In order to explore the relationship between anti-apoptotic signaling and N-cadherin, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in western blot on human samples (fig 4). J Biol Chem (2002) ncbi |
| mouse monoclonal (HECD-1) |
| In order to investigate how Cas phosphorylation and Src kinase activation regulate TGF-beta signal transduction, Invitrogen Cdh1 antibody (Zymed Laboratories, HECD-1) was used in blocking or activating experiments on human samples . J Biol Chem (2002) ncbi |
| mouse monoclonal (HECD-1) |
| In order to investigate the relationship between primary mucoepidermoid carcinoma of the thyroid and papillary thyroid carcinoma, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 1). Virchows Arch (2002) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study the regulation of adherens junctions, Invitrogen Cdh1 antibody (Zymed, 13-1700) was used in immunocytochemistry on human samples at 1:100 (fig 1) and in western blot on human samples at 1:1000 (fig 1). Nat Cell Biol (2002) ncbi |
| mouse monoclonal (HECD-1) |
| In order to investigate the expression of E-, N-, and P-cadherin in ductal carcinoma in situ of the breast, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 2). Virchows Arch (2002) ncbi |
| mouse monoclonal (HECD-1) |
| In order to review the national action plan of the Breast Cancer Workshop on Multicultural Aspects of Breast Cancer Etiology, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry on human samples . Cancer (2002) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study beta1-integrin during cell movement, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in blocking or activating experiments on human samples . Cancer Res (2002) ncbi |
| mouse monoclonal (HECD-1) |
| In order to investigate the cis sequences and transcription factors that regulate E-cadherin expression in breast cancer cells, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in western blot on human samples at 1:5000. Cancer Res (2002) ncbi |
| mouse monoclonal (HECD-1) |
| In order to examine epithelial-type cadherin and neural-type cadherin as diagnostic markers of malignant noncarcinomatous neoplasms, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples . Arch Pathol Lab Med (2002) ncbi |
| mouse monoclonal (HECD-1) |
| In order to determine how adhesion systems contribute to enterocyte differentiation, Invitrogen Cdh1 antibody (Zymed, clone HECD-1) was used in immunocytochemistry on human samples (fig 4) and in western blot on human samples (fig 2). J Cell Sci (2002) ncbi |
| mouse monoclonal (HECD-1) |
| In order to evaluate optimal specimen preparation for the immunostaining of effusion samples, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunocytochemistry on human samples at 1:100. Diagn Cytopathol (2002) ncbi |
| mouse monoclonal (HECD-1) |
| In order to investigate immortalized human ovarian surface epithelial, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in western blot on human samples (fig 5). Clin Cancer Res (2001) ncbi |
| mouse monoclonal (HECD-1) |
| In order to report that E-CD expression in human breast cancer has minimal prognostic value, but may serves as a phenotypic marker, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples . Br J Cancer (2001) ncbi |
| mouse monoclonal (HECD-1) |
| In order to test if tight junction antigens are present in adult and developing human epidermis, Invitrogen Cdh1 antibody (Zymed, 13?C1700) was used in immunohistochemistry - paraffin section on human samples (fig 3). J Invest Dermatol (2001) ncbi |
| mouse monoclonal (HECD-1) |
| In order to examine the prevalence and nature of E-cadherin alterations in sporadic gastric carcinomas, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - frozen section on human samples at 1:200. Mod Pathol (2001) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study different genes involved in oncogenesis of colon and rectal cancers and examine their prognostic value, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:1000. J Pathol (2001) ncbi |
| mouse monoclonal (HECD-1) |
| In order to assess E-cadherin expression in primary cultures and determine the relationship between E-cadherin expression and prostate-specific antigen secretion, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:20 (fig 1) and in western blot on human samples (fig 2). Urol Res (2001) ncbi |
| mouse monoclonal (HECD-1) |
| In order to discuss using expression of cadherins and catenins as prognosis markers for cancer, Invitrogen Cdh1 antibody (Zymed, clone HECD-1) was used in immunohistochemistry - paraffin section on human samples (tbl 1). J Mammary Gland Biol Neoplasia (2001) ncbi |
| mouse monoclonal (HECD-1) |
| In order to describe a patient affected by endometrial cancer and treated primarily with leuprolide, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry on human samples at 1:800. Br J Cancer (2001) ncbi |
| mouse monoclonal (HECD-1) |
| In order to determine E-cadherin expression in a broad range of prostate tissue, Invitrogen Cdh1 antibody (Zymed Laboratories, clone HECD-1) was used in immunohistochemistry - paraffin section on human samples (fig 1). Hum Pathol (2001) ncbi |
| mouse monoclonal (HECD-1) |
| In order to describe the clinicopathological features of papillary thyroid carcinoma, Invitrogen Cdh1 antibody (Zymed, clone HECD-1) was used in immunohistochemistry on human samples (fig 1). J Pathol (2001) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study lymphovascular invasion in breast cancer, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in blocking or activating experiments on human samples , in immunoprecipitation on human samples (fig 3d), in immunohistochemistry on human samples (fig 3f) and in western blot on human samples (fig 2). Cancer Res (2001) ncbi |
| mouse monoclonal (HECD-1) |
| In order to examine connexin expression in the developing human epidermis, Invitrogen Cdh1 antibody (Zymed, 13-1700) was used in immunohistochemistry - frozen section on human samples at 1:10. Arch Dermatol Res (2001) ncbi |
| mouse monoclonal (HECD-1) |
| In order to elucidate the role of MUC1 in breast carcinoma, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:200. Cancer (2001) ncbi |
| mouse monoclonal (HECD-1) |
| In order to examine adhesion- versus a beta-catenin signaling-dependent mechanisms of E-cadherin tumor suppressor activity, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in western blot on human samples . J Cell Biol (2001) ncbi |
| mouse monoclonal (HECD-1) |
| In order to analyze the morphological, kinetic, and molecular characteristics of low-grade and high-grade dysplasias in comparison with intestinal metaplasia type III, normal mucosa, and early gastric cancer of the intestinal type, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:2000 (fig 2). Int J Oncol (2001) ncbi |
| mouse monoclonal (HECD-1) |
| In order to discuss the classification and grading systems for ductal carcinoma in situ of the breast, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry on human samples at 1:100. Am J Clin Pathol (2001) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study E cadherin expression in lobular carcinoma in situ, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:500. Mol Pathol (2001) ncbi |
| mouse monoclonal (HECD-1) |
| In order to identify genetic alterations in lobular carcinoma in situ, Invitrogen Cdh1 antibody (Zymed Laboratories, clone HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:1000 (fig 1). Hum Pathol (2001) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study genetic alterations in tubular carcinomas of the breast, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry on human samples at 1:1000 (tbl 3). Hum Pathol (2001) ncbi |
| mouse monoclonal (HECD-1) |
| In order to investigate E-cadherin in prostate cancer samples, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in western blot on human samples . Cancer Res (2001) ncbi |
| mouse monoclonal (HECD-1) |
| In order to determine E-cadherin expression in in situ and invasive carcinomas, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:200. Am J Clin Pathol (2001) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study E-cadherin in in situ carcinomas, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry on human samples at 1:100 (fig 5). Am J Surg Pathol (2001) ncbi |
| mouse monoclonal (HECD-1) |
| In order to discuss the relationship between the adhesive characteristics of hematopoietic cells and their maturation, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry on human samples at 1:200. Arch Pathol Lab Med (2001) ncbi |
| mouse monoclonal (HECD-1) |
| In order to investigate the role of N-cadherin in cardiogenesis, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on mouse samples at 1:100. Development (2001) ncbi |
| mouse monoclonal (HECD-1) |
| In order to characterize a human midgut carcinoid tumor after transplantation into nude mice, Invitrogen Cdh1 antibody (zymed, 13-1700) was used in immunohistochemistry - paraffin section on human samples . Am J Pathol (2001) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study E-cadherin in hematopoietic tissues, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in western blot on human samples . Clin Cancer Res (2000) ncbi |
| mouse monoclonal (HECD-1) |
| In order to examine stromelysin-2 and other matrix metalloproteinase expression during wound healing, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry on human samples . J Invest Dermatol (2000) ncbi |
| mouse monoclonal (HECD-1) |
| In order to investigate how time at confluence affects cultured human retinal pigment epithelium cells, Invitrogen Cdh1 antibody (Zymed Laboratories, clone HECD-1) was used in immunocytochemistry on human samples and in western blot on human samples (fig 2). Invest Ophthalmol Vis Sci (2000) ncbi |
| mouse monoclonal (HECD-1) |
| In order to determine the distribution of Na/K ATPase and E-cadherin in retinal pigment epithelium cells, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - frozen section on cow samples and in immunohistochemistry on cow samples . Invest Ophthalmol Vis Sci (2000) ncbi |
| mouse monoclonal (HECD-1) |
| In order to examine the role of E-cadherin in melanoma-keratinocyte interaction, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in flow cytometry on human samples . Am J Pathol (2000) ncbi |
| mouse monoclonal (HECD-1) |
| In order to measure the expression of p53, p21, bcl-2 bax, pRb, and cyclin D1 for evaluation of their roles in colon-cancer progression, Invitrogen Cdh1 antibody (Zymed, 13-1700) was used in immunohistochemistry - paraffin section on human samples at 1:500 (tbl 1). Virchows Arch (2000) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study the cellular origin of bladder carcinosarcoma, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples (fig 1). Eur Urol (2000) ncbi |
| mouse monoclonal (HECD-1) |
| In order to validate the use of polymerase chain reaction-amplified full-length cDNA as a substitute for mRNA in nucleic acid array and gene expression analysis, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - frozen section on human samples . Invest Ophthalmol Vis Sci (1999) ncbi |
| mouse monoclonal (HECD-1) |
| In order to analyze 40 human lobular breast cancers for loss of heterozygosity and other mutations, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples . Br J Cancer (1999) ncbi |
| mouse monoclonal (HECD-1) |
| In order to determine the role of tyrosine phosphorylation in regulating intercellular adhesion of intestinal cells, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunocytochemistry on human samples at 1:400. Biochim Biophys Acta (1999) ncbi |
| mouse monoclonal (HECD-1) |
| In order to test if retinal pigment epithelial express E-cadherin, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunocytochemistry on human samples . Invest Ophthalmol Vis Sci (1999) ncbi |
| mouse monoclonal (HECD-1) |
| In order to discuss the role of cadherins in tumor development, Invitrogen Cdh1 antibody (Zymed, clone HECD-1) was used in immunohistochemistry - paraffin section on human samples (fig 3). Cancer (1999) ncbi |
| mouse monoclonal (HECD-1) |
| In order to determine the localization of type XIII collagen in normal human skin and cultured keratinocytes, Invitrogen Cdh1 antibody (Zymed, 13?C1700) was used in immunohistochemistry - frozen section on human samples (fig 1). J Invest Dermatol (1999) ncbi |
| mouse monoclonal (HECD-1) |
| In order to report the gain of N-cadherin and loss of E-cadherin by invasive prostate carcinoma cell lines, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunoprecipitation on human samples (fig 2), in immunocytochemistry on human samples (fig 3) and in western blot on human samples (fig 2). Am J Pathol (1999) ncbi |
| mouse monoclonal (HECD-1) |
| In order to assess the loss of E-cadherin expression in early gastric carcinomas, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:800 (fig 1). Histopathology (1999) ncbi |
| mouse monoclonal (HECD-1) |
| In order to study the relationship of cadherins E, N and P to ovarian surface epithelium morphology, growth patterns and differentiation, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunocytochemistry on human samples . Int J Cancer (1999) ncbi |
| mouse monoclonal (HECD-1) |
| In order to assess the role of E-cadherin and retinoblastoma tumor suppressor in cell survival and programed cell death, Invitrogen Cdh1 antibody (Zymed, 13-1700) was used in western blot on human samples . J Biol Chem (1999) ncbi |
| mouse monoclonal (HECD-1) |
| In order to characterize the localization and function of the EDA protein, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 2). Exp Dermatol (1998) ncbi |
| mouse monoclonal (HECD-1) |
| In order to propose that ubiquitin-conjugating E2 enzyme variant proteins control differentiation by altering cell cycle distribution, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunocytochemistry on human samples . Mol Cell Biol (1998) ncbi |
| mouse monoclonal (HECD-1) |
| In order to determine the effect of UV radiation on Langerhans' cells co-stimulatory molecules in vivo, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in flow cytometry on human samples at 1:1000 (fig 2). Eur J Immunol (1997) ncbi |
| mouse monoclonal (HECD-1) |
| In order to identify markers to determine lymph node metastases in patients with gastric cancer, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples . Br J Cancer (1996) ncbi |
| mouse monoclonal (HECD-1) |
| In order to assess E-cadherin expression in paraffin-embedded whole prostates and metastatic prostate cancer, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in immunohistochemistry - paraffin section on human samples at 5 ug/ml. Am J Pathol (1996) ncbi |
| mouse monoclonal (HECD-1) |
| In order to determine the expression of cellular adhesion molecules on different human prostate tumor cell lines, Invitrogen Cdh1 antibody (Zymed, HECD-1) was used in flow cytometry on human samples . Prostate (1995) ncbi |
Articles Reviewed
- Runge T, Shaheen N, Djukic Z, Hallquist S, Orlando R. Cleavage of E-Cadherin Contributes to Defective Barrier Function in Neosquamous Epithelium. Dig Dis Sci. 2016;61:3169-3175 pubmed
- Lizalek J, McKenna T, Huegel K, Marsh S, Carolan A, Kobliska A, et al. Lysophosphatidic Acid Stimulates Urokinase Receptor (uPAR/CD87) in Ovarian Epithelial Cancer Cells. Anticancer Res. 2015;35:5263-70 pubmed
- Lindström A, Hellberg D. Immunohistochemical LRIG3 expression in cervical intraepithelial neoplasia and invasive squamous cell cervical cancer: association with expression of tumor markers, hormones, high-risk HPV-infection, smoking and patient outcome. Eur J Histochem. 2014;58:2227 pubmed publisher
- Jang S, Han H, Jun Y, Jang S, Min K, Sim J, et al. Clinicopathological significance of CADM4 expression, and its correlation with expression of E-cadherin and Ki-67 in colorectal adenocarcinomas. J Clin Pathol. 2012;65:902-6 pubmed
- Ye Y, Tellez J, Durazo M, Belcher M, Yearsley K, Barsky S. E-cadherin accumulation within the lymphovascular embolus of inflammatory breast cancer is due to altered trafficking. Anticancer Res. 2010;30:3903-10 pubmed
- Agnarsson B, Ingthorsson S, Gudjonsson T, Leosson K. Evanescent-wave fluorescence microscopy using symmetric planar waveguides. Opt Express. 2009;17:5075-82 pubmed
- Ivascu A, Kubbies M. Diversity of cell-mediated adhesions in breast cancer spheroids. Int J Oncol. 2007;31:1403-13 pubmed
- Akat K, Bleck C, Lee Y, Haselmann Weiss U, Kartenbeck J. Characterization of a novel type of adherens junction in meningiomas and the derived cell line HBL-52. Cell Tissue Res. 2008;331:401-12 pubmed
- Haga T, Uchide N, Tugizov S, Palefsky J. Role of E-cadherin in the induction of apoptosis of HPV16-positive CaSki cervical cancer cells during multicellular tumor spheroid formation. Apoptosis. 2008;13:97-108 pubmed
- Xie J, Haslam S. Extracellular matrix, Rac1 signaling, and estrogen-induced proliferation in MCF-7 breast cancer cells. Breast Cancer Res Treat. 2008;110:257-68 pubmed
- Troyanovsky R, Laur O, Troyanovsky S. Stable and unstable cadherin dimers: mechanisms of formation and roles in cell adhesion. Mol Biol Cell. 2007;18:4343-52 pubmed
- Chung Y, Lam A, Luk J, Law S, Chan K, Lee P, et al. Altered E-cadherin expression and p120 catenin localization in esophageal squamous cell carcinoma. Ann Surg Oncol. 2007;14:3260-7 pubmed
- Mahomed F, Altini M, Meer S. Altered E-cadherin/beta-catenin expression in oral squamous carcinoma with and without nodal metastasis. Oral Dis. 2007;13:386-92 pubmed
- Canavese G, Bernardi A, Candelaresi G, Lovadina P, Amerio S, Rossetti V, et al. Expression of the E-cadherin-catenins complex in sentinel node is related to tumor morphology but not to spread to nonsentinel nodes. Pathol Res Pract. 2007;203:517-23 pubmed
- Symowicz J, Adley B, Gleason K, Johnson J, Ghosh S, Fishman D, et al. Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res. 2007;67:2030-9 pubmed
- Chang Y, Marlin J, Chance T, Jakobi R. RhoA mediates cyclooxygenase-2 signaling to disrupt the formation of adherens junctions and increase cell motility. Cancer Res. 2006;66:11700-8 pubmed
- Rakha E, El Sayed M, Green A, Lee A, Robertson J, Ellis I. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25-32 pubmed
- Murao K, Kubo Y, Ohtani N, Hara E, Arase S. Epigenetic abnormalities in cutaneous squamous cell carcinomas: frequent inactivation of the RB1/p16 and p53 pathways. Br J Dermatol. 2006;155:999-1005 pubmed
- Sonne S, Hoei Hansen C, Nielsen J, Herlihy A, Andersson A, Almstrup K, et al. CDH1 (E-cadherin) in testicular germ cell neoplasia: suppressed translation of mRNA in pre-invasive carcinoma in situ but increased protein levels in advanced tumours. APMIS. 2006;114:549-58 pubmed
- Robert G, Gaggioli C, Bailet O, Chavey C, Abbe P, Aberdam E, et al. SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. Cancer Res. 2006;66:7516-23 pubmed
- Rodriguez Sanjuan J, Fontalba A, Mayorga M, Bordin M, Hyland S, Trugeda S, et al. A novel mutation in the E-cadherin gene in the first family with hereditary diffuse gastric cancer reported in Spain. Eur J Surg Oncol. 2006;32:1110-3 pubmed
- Bacani J, Soares M, Zwingerman R, Di Nicola N, Senz J, Riddell R, et al. CDH1/E-cadherin germline mutations in early-onset gastric cancer. J Med Genet. 2006;43:867-72 pubmed
- Katso R, Pardo O, Palamidessi A, Franz C, Marinov M, De Laurentiis A, et al. Phosphoinositide 3-Kinase C2beta regulates cytoskeletal organization and cell migration via Rac-dependent mechanisms. Mol Biol Cell. 2006;17:3729-44 pubmed
- Troyanovsky R, Sokolov E, Troyanovsky S. Endocytosis of cadherin from intracellular junctions is the driving force for cadherin adhesive dimer disassembly. Mol Biol Cell. 2006;17:3484-93 pubmed
- Fujita Y, Hogan C, Braga V. Regulation of cell-cell adhesion by Rap1. Methods Enzymol. 2006;407:359-72 pubmed
- Rao K, Alper O, Opheim K, Bonnet G, Wolfe K, Bryant E, et al. Cytogenetic characterization and H-ras associated transformation of immortalized human mammary epithelial cells. Cancer Cell Int. 2006;6:15 pubmed
- Lascombe I, Clairotte A, Fauconnet S, Bernardini S, Wallerand H, Kantelip B, et al. N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors. Clin Cancer Res. 2006;12:2780-7 pubmed
- Lombaerts M, van Wezel T, Philippo K, Dierssen J, Zimmerman R, Oosting J, et al. E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br J Cancer. 2006;94:661-71 pubmed
- Voutilainen K, Anttila M, Sillanpää S, Ropponen K, Saarikoski S, Juhola M, et al. Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer. J Clin Pathol. 2006;59:460-7 pubmed
- Rakha E, Putti T, Abd El Rehim D, Paish C, Green A, Powe D, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol. 2006;208:495-506 pubmed
- Harigopal M, Shin S, Murray M, Tickoo S, Brogi E, Rosen P. Aberrant E-cadherin staining patterns in invasive mammary carcinoma. World J Surg Oncol. 2005;3:73 pubmed
- Taylor D, Watt N, Perera W, Hooper N. Assigning functions to distinct regions of the N-terminus of the prion protein that are involved in its copper-stimulated, clathrin-dependent endocytosis. J Cell Sci. 2005;118:5141-53 pubmed
- Han S, Lee H, Lee J, Kim W, Nam H, Kim H, et al. Modulation of E-cadherin by hepatocyte growth factor induces aggressiveness of gastric carcinoma. Ann Surg. 2005;242:676-83 pubmed
- Asioli S, Marucci G, Ficarra G, Stephens M, Foschini M, Ellis I, et al. Polymorphous adenocarcinoma of the breast. Report of three cases. Virchows Arch. 2006;448:29-34 pubmed
- Veveris Lowe T, Lawrence M, Collard R, Bui L, Herington A, Nicol D, et al. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr Relat Cancer. 2005;12:631-43 pubmed
- Schmidt C, Gi Y, Patel T, Coffey R, Beauchamp R, Pearson A. E-cadherin is regulated by the transcriptional repressor SLUG during Ras-mediated transformation of intestinal epithelial cells. Surgery. 2005;138:306-12 pubmed
- Margulis A, Zhang W, Alt Holland A, Pawagi S, Prabhu P, Cao J, et al. Loss of intercellular adhesion activates a transition from low- to high-grade human squamous cell carcinoma. Int J Cancer. 2006;118:821-31 pubmed
- Köbel M, Pohl G, Schmitt W, Hauptmann S, Wang T, Shih I. Activation of mitogen-activated protein kinase is required for migration and invasion of placental site trophoblastic tumor. Am J Pathol. 2005;167:879-85 pubmed
- Rakha E, Abd El Rehim D, Pinder S, Lewis S, Ellis I. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology. 2005;46:685-93 pubmed
- Vongwiwatana A, Tasanarong A, Rayner D, Melk A, Halloran P. Epithelial to mesenchymal transition during late deterioration of human kidney transplants: the role of tubular cells in fibrogenesis. Am J Transplant. 2005;5:1367-74 pubmed
- Kuefer R, Hofer M, Zorn C, Engel O, Volkmer B, Juarez Brito M, et al. Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer. Br J Cancer. 2005;92:2018-23 pubmed
- Abd El Rehim D, Ball G, Pinder S, Rakha E, Paish C, Robertson J, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer. 2005;116:340-50 pubmed
- Bendardaf R, Elzagheid A, Lamlum H, Ristamaki R, Collan Y, Pyrhonen S. E-cadherin, CD44s and CD44v6 correlate with tumour differentiation in colorectal cancer. Oncol Rep. 2005;13:831-5 pubmed
- Ivanov A, Hunt D, Utech M, Nusrat A, Parkos C. Differential roles for actin polymerization and a myosin II motor in assembly of the epithelial apical junctional complex. Mol Biol Cell. 2005;16:2636-50 pubmed
- Pelosi G, Scarpa A, Puppa G, Veronesi G, Spaggiari L, Pasini F, et al. Alteration of the E-cadherin/beta-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids. Cancer. 2005;103:1154-64 pubmed
- van Velthuysen M, Taal B, van der Hoeven J, Peterse J. Expression of oestrogen receptor and loss of E-cadherin are diagnostic for gastric metastasis of breast carcinoma. Histopathology. 2005;46:153-7 pubmed
- Rothen Rutishauser B, Kiama S, Gehr P. A three-dimensional cellular model of the human respiratory tract to study the interaction with particles. Am J Respir Cell Mol Biol. 2005;32:281-9 pubmed
- Rakha E, Armour J, Pinder S, Paish C, Ellis I. High-resolution analysis of 16q22.1 in breast carcinoma using DNA amplifiable probes (multiplex amplifiable probe hybridization technique) and immunohistochemistry. Int J Cancer. 2005;114:720-9 pubmed
- Bane A, Tjan S, Parkes R, Andrulis I, O Malley F. Invasive lobular carcinoma: to grade or not to grade. Mod Pathol. 2005;18:621-8 pubmed
- Rios Doria J, Day M. Truncated E-cadherin potentiates cell death in prostate epithelial cells. Prostate. 2005;63:259-68 pubmed
- Eriksen J, Buffa F, Alsner J, Steiniche T, Bentzen S, Overgaard J. Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomas. Radiother Oncol. 2004;72:275-82 pubmed
- Honecker F, Kersemaekers A, Molier M, Van Weeren P, Stoop H, de Krijger R, et al. Involvement of E-cadherin and beta-catenin in germ cell tumours and in normal male fetal germ cell development. J Pathol. 2004;204:167-74 pubmed
- Schmidt C, Gi Y, Coffey R, Beauchamp R, Pearson A. Oncogenic Ras dominates overexpression of E-cadherin in malignant transformation of intestinal epithelial cells. Surgery. 2004;136:303-9 pubmed
- Marques F, Fonsechi Carvasan G, de Angelo Andrade L, Bottcher Luiz F. Immunohistochemical patterns for alpha- and beta-catenin, E- and N-cadherin expression in ovarian epithelial tumors. Gynecol Oncol. 2004;94:16-24 pubmed
- Kapoor P, Saunders M, Li Z, Zhou Z, Sheaffer N, Kunze E, et al. Breast cancer metastatic potential: correlation with increased heterotypic gap junctional intercellular communication between breast cancer cells and osteoblastic cells. Int J Cancer. 2004;111:693-7 pubmed
- Andersen K, Nesland J, Holm R, Flørenes V, Fodstad Ø, Maelandsmo G. Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Mod Pathol. 2004;17:990-7 pubmed
- Song S, Kim S, Kim D, Son H, Rhee J, Kim Y. Abnormal expression of E-cadherin in early gastric carcinoma: its relationship with macroscopic growth patterns and catenin alpha and beta. J Clin Gastroenterol. 2004;38:252-9 pubmed
- Graziano F, Arduini F, Ruzzo A, Bearzi I, Humar B, More H, et al. Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer. Clin Cancer Res. 2004;10:2784-9 pubmed
- Bassarova A, Nesland J, Sedloev T, Danielsen H, Christova S. Pilomatrix carcinoma with lymph node metastases. J Cutan Pathol. 2004;31:330-5 pubmed
- Graziano F, Arduini F, Ruzzo A, Mandolesi A, Bearzi I, Silva R, et al. Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs. Ann Oncol. 2004;15:489-92 pubmed
- Chunthapong J, Seftor E, Khalkhali Ellis Z, Seftor R, Amir S, Lubaroff D, et al. Dual roles of E-cadherin in prostate cancer invasion. J Cell Biochem. 2004;91:649-61 pubmed
- Chen Q, Lipkina G, Song Q, Kramer R. Promoter methylation regulates cadherin switching in squamous cell carcinoma. Biochem Biophys Res Commun. 2004;315:850-6 pubmed
- Tobey N, Argote C, Hosseini S, Orlando R. Calcium-switch technique and junctional permeability in native rabbit esophageal epithelium. Am J Physiol Gastrointest Liver Physiol. 2004;286:G1042-9 pubmed
- Kuefer R, Hofer M, Gschwend J, Pienta K, Sanda M, Chinnaiyan A, et al. The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. Clin Cancer Res. 2003;9:6447-52 pubmed
- Han S, Kim H, Seong D, Kim Y, Park Y, Bang Y, et al. Loss of the Smad3 expression increases susceptibility to tumorigenicity in human gastric cancer. Oncogene. 2004;23:1333-41 pubmed
- Gottardi C, Gumbiner B. Role for ICAT in beta-catenin-dependent nuclear signaling and cadherin functions. Am J Physiol Cell Physiol. 2004;286:C747-56 pubmed
- Troyanovsky R, Sokolov E, Troyanovsky S. Adhesive and lateral E-cadherin dimers are mediated by the same interface. Mol Cell Biol. 2003;23:7965-72 pubmed
- Ordonez N. Value of E-cadherin and N-cadherin immunostaining in the diagnosis of mesothelioma. Hum Pathol. 2003;34:749-55 pubmed
- Palacios J, Sarrio D, García Macias M, Bryant B, Sobel M, Merino M. Frequent E-cadherin gene inactivation by loss of heterozygosity in pleomorphic lobular carcinoma of the breast. Mod Pathol. 2003;16:674-8 pubmed
- Rocha A, Soares P, Fonseca E, Cameselle Teijeiro J, Oliveira M, Sobrinho Simoes M. E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas. Histopathology. 2003;42:580-7 pubmed
- McGuire J, Li Q, Parks W. Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. Am J Pathol. 2003;162:1831-43 pubmed
- Kokenyesi R, Murray K, Benshushan A, Huntley E, Kao M. Invasion of interstitial matrix by a novel cell line from primary peritoneal carcinosarcoma, and by established ovarian carcinoma cell lines: role of cell-matrix adhesion molecules, proteinases, and E-cadherin expression. Gynecol Oncol. 2003;89:60-72 pubmed
- Offterdinger M, Schneider S, Grunt T. Heregulin and retinoids synergistically induce branching morphogenesis of breast cancer cells cultivated in 3D collagen gels. J Cell Physiol. 2003;195:260-75 pubmed
- Impola U, Toriseva M, Suomela S, Jeskanen L, Hieta N, Jahkola T, et al. Matrix metalloproteinase-19 is expressed by proliferating epithelium but disappears with neoplastic dedifferentiation. Int J Cancer. 2003;103:709-16 pubmed
- Carpenter P, Al Kuran R, Theuer C. Paranuaclear E-cadherin in gastric adenocarcinoma. Am J Clin Pathol. 2002;118:887-94 pubmed
- Kuijper A, Preisler Adams S, Rahusen F, Gille J, van der Wall E, van Diest P. Multiple fibroadenomas harbouring carcinoma in situ in a woman with a family history of breast/ovarian cancer. J Clin Pathol. 2002;55:795-7 pubmed
- Karbova E, Davidson B, Metodiev K, Trope C, Nesland J. Adenomatous polyposis coli (APC) protein expression in primary and metastatic serous ovarian carcinoma. Int J Surg Pathol. 2002;10:175-80 pubmed
- Damiani S, Eusebi V, Peterse J. Malignant neoplasms infiltrating pseudoangiomatous' stromal hyperplasia of the breast: an unrecognized pathway of tumour spread. Histopathology. 2002;41:208-15 pubmed
- Jamal S, Schneider R. UV-induction of keratinocyte endothelin-1 downregulates E-cadherin in melanocytes and melanoma cells. J Clin Invest. 2002;110:443-52 pubmed
- Khorram Manesh A, Ahlman H, Jansson S, Nilsson O. N-cadherin expression in adrenal tumors: upregulation in malignant pheochromocytoma and downregulation in adrenocortical carcinoma. Endocr Pathol. 2002;13:99-110 pubmed
- Elzagheid A, Kuopio T, Ilmen M, Collan Y. Prognostication of invasive ductal breast cancer by quantification of E-cadherin immunostaining: the methodology and clinical relevance. Histopathology. 2002;41:127-33 pubmed
- Tran N, Adams D, Vaillancourt R, Heimark R. Signal transduction from N-cadherin increases Bcl-2. Regulation of the phosphatidylinositol 3-kinase/Akt pathway by homophilic adhesion and actin cytoskeletal organization. J Biol Chem. 2002;277:32905-14 pubmed
- Kim J, Joo C. Involvement of cell-cell interactions in the rapid stimulation of Cas tyrosine phosphorylation and Src kinase activity by transforming growth factor-beta 1. J Biol Chem. 2002;277:31938-48 pubmed
- Rocha A, Soares P, Machado J, Máximo V, Fonseca E, Franssila K, et al. Mucoepidermoid carcinoma of the thyroid: a tumour histotype characterised by P-cadherin neoexpression and marked abnormalities of E-cadherin/catenins complex. Virchows Arch. 2002;440:498-504 pubmed
- Sahai E, Marshall C. ROCK and Dia have opposing effects on adherens junctions downstream of Rho. Nat Cell Biol. 2002;4:408-15 pubmed
- Paredes J, Milanezi F, Viegas L, Amendoeira I, Schmitt F. P-cadherin expression is associated with high-grade ductal carcinoma in situ of the breast. Virchows Arch. 2002;440:16-21 pubmed
- Mert G. National action plan on Breast Cancer Workshop on Multicultural Aspects of Breast Cancer Etiology: recommendations of the workshop. Cancer. 2002;94:2113 pubmed
- Hegerfeldt Y, Tusch M, Brocker E, Friedl P. Collective cell movement in primary melanoma explants: plasticity of cell-cell interaction, beta1-integrin function, and migration strategies. Cancer Res. 2002;62:2125-30 pubmed
- Hajra K, Chen D, Fearon E. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 2002;62:1613-8 pubmed
- Laskin W, Miettinen M. Epithelial-type and neural-type cadherin expression in malignant noncarcinomatous neoplasms with epithelioid features that involve the soft tissues. Arch Pathol Lab Med. 2002;126:425-31 pubmed
- Schreider C, Peignon G, Thenet S, Chambaz J, Pincon Raymond M. Integrin-mediated functional polarization of Caco-2 cells through E-cadherin--actin complexes. J Cell Sci. 2002;115:543-52 pubmed
- Fetsch P, Simsir A, Brosky K, Abati A. Comparison of three commonly used cytologic preparations in effusion immunocytochemistry. Diagn Cytopathol. 2002;26:61-6 pubmed
- Gregoire L, Rabah R, Schmelz E, Munkarah A, Roberts P, Lancaster W. Spontaneous malignant transformation of human ovarian surface epithelial cells in vitro. Clin Cancer Res. 2001;7:4280-7 pubmed
- Parker C, Rampaul R, Pinder S, Bell J, Wencyk P, Blamey R, et al. E-cadherin as a prognostic indicator in primary breast cancer. Br J Cancer. 2001;85:1958-63 pubmed
- Pummi K, Malminen M, Aho H, Karvonen S, Peltonen J, Peltonen S. Epidermal tight junctions: ZO-1 and occludin are expressed in mature, developing, and affected skin and in vitro differentiating keratinocytes. J Invest Dermatol. 2001;117:1050-8 pubmed
- Ascaño J, Frierson H, Moskaluk C, Harper J, Roviello F, Jackson C, et al. Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer. Mod Pathol. 2001;14:942-9 pubmed
- Kapiteijn E, Liefers G, Los L, Kranenbarg E, Hermans J, Tollenaar R, et al. Mechanisms of oncogenesis in colon versus rectal cancer. J Pathol. 2001;195:171-8 pubmed
- Krill D, Thomas A, Wu S, Dhir R, Becich M. E-cadherin expression and PSA secretion in human prostate epithelial cells. Urol Res. 2001;29:287-92 pubmed
- Wheelock M, Soler A, Knudsen K. Cadherin junctions in mammary tumors. J Mammary Gland Biol Neoplasia. 2001;6:275-85 pubmed
- Noci I, Borri P, Bonfirraro G, Chieffi O, Arcangeli A, Cherubini A, et al. Longstanding survival without cancer progression in a patient affected by endometrial carcinoma treated primarily with leuprolide. Br J Cancer. 2001;85:333-6 pubmed
- Rubin M, Mucci N, Figurski J, Fecko A, Pienta K, Day M. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Hum Pathol. 2001;32:690-7 pubmed
- Rocha A, Soares P, Seruca R, Máximo V, Matias Guiu X, Cameselle Teijeiro J, et al. Abnormalities of the E-cadherin/catenin adhesion complex in classical papillary thyroid carcinoma and in its diffuse sclerosing variant. J Pathol. 2001;194:358-66 pubmed
- Tomlinson J, Alpaugh M, Barsky S. An intact overexpressed E-cadherin/alpha,beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res. 2001;61:5231-41 pubmed
- Hentula M, Peltonen J, Peltonen S. Expression profiles of cell-cell and cell-matrix junction proteins in developing human epidermis. Arch Dermatol Res. 2001;293:259-67 pubmed
- Rahn J, Dabbagh L, Pasdar M, Hugh J. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer. 2001;91:1973-82 pubmed
- Gottardi C, Wong E, Gumbiner B. E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner. J Cell Biol. 2001;153:1049-60 pubmed
- Spina D, Vindigni C, Presenti L, Schurfeld K, Stumpo M, Tosi P. Cell proliferation, cell death, E-cadherin, metalloproteinase expression and angiogenesis in gastric cancer precursors and early cancer of the intestinal type. Int J Oncol. 2001;18:1251-8 pubmed
- Leong A, Sormunen R, Vinyuvat S, Hamdani R, Suthipintawong C. Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems. Am J Clin Pathol. 2001;115:709-18 pubmed
- Rieger Christ K, Pezza J, Dugan J, Braasch J, Hughes K, Summerhayes I. Disparate E-cadherin mutations in LCIS and associated invasive breast carcinomas. Mol Pathol. 2001;54:91-7 pubmed
- Etzell J, DeVries S, Chew K, Florendo C, Molinaro A, Ljung B, et al. Loss of chromosome 16q in lobular carcinoma in situ. Hum Pathol. 2001;32:292-6 pubmed
- Waldman F, Hwang E, Etzell J, Eng C, DeVries S, Bennington J, et al. Genomic alterations in tubular breast carcinomas. Hum Pathol. 2001;32:222-6 pubmed
- Rashid M, Sanda M, Vallorosi C, Rios Doria J, Rubin M, Day M. Posttranslational truncation and inactivation of human E-cadherin distinguishes prostate cancer from matched normal prostate. Cancer Res. 2001;61:489-92 pubmed
- Acs G, Lawton T, Rebbeck T, LiVolsi V, Zhang P. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol. 2001;115:85-98 pubmed
- Maluf H, Swanson P, Koerner F. Solid low-grade in situ carcinoma of the breast: role of associated lesions and E-cadherin in differential diagnosis. Am J Surg Pathol. 2001;25:237-44 pubmed
- Acs G, LiVolsi V. Loss of membrane expression of E-cadherin in leukemic erythroblasts. Arch Pathol Lab Med. 2001;125:198-201 pubmed
- Luo Y, Ferreira Cornwell M, Baldwin H, Kostetskii I, Lenox J, Lieberman M, et al. Rescuing the N-cadherin knockout by cardiac-specific expression of N- or E-cadherin. Development. 2001;128:459-69 pubmed
- Kolby L, Bernhardt P, Ahlman H, Wangberg B, Johanson V, Wigander A, et al. A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake. Am J Pathol. 2001;158:745-55 pubmed
- Corn P, Smith B, Ruckdeschel E, Douglas D, Baylin S, Herman J. E-cadherin expression is silenced by 5' CpG island methylation in acute leukemia. Clin Cancer Res. 2000;6:4243-8 pubmed
- Rechardt O, Elomaa O, Vaalamo M, Pääkkönen K, Jahkola T, Hook Nikanne J, et al. Stromelysin-2 is upregulated during normal wound repair and is induced by cytokines. J Invest Dermatol. 2000;115:778-87 pubmed
- Kaida M, Cao F, Skumatz C, Irving P, Burke J. Time at confluence for human RPE cells: effects on the adherens junction and in vitro wound closure. Invest Ophthalmol Vis Sci. 2000;41:3215-24 pubmed
- Burke J, Cao F, Irving P. High levels of E-/P-cadherin: correlation with decreased apical polarity of Na/K ATPase in bovine RPE cells in situ. Invest Ophthalmol Vis Sci. 2000;41:1945-52 pubmed
- Hsu M, Meier F, Nesbit M, Hsu J, Van Belle P, Elder D, et al. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol. 2000;156:1515-25 pubmed
- Bukholm I, Nesland J. Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas. Virchows Arch. 2000;436:224-8 pubmed
- Halachmi S, Demarzo A, Chow N, Halachmi N, Smith A, Linn J, et al. Genetic alterations in urinary bladder carcinosarcoma: evidence of a common clonal origin. Eur Urol. 2000;37:350-7 pubmed
- Spirin K, Ljubimov A, Castellon R, Wiedoeft O, Marano M, Sheppard D, et al. Analysis of gene expression in human bullous keratopathy corneas containing limiting amounts of RNA. Invest Ophthalmol Vis Sci. 1999;40:3108-15 pubmed
- Huiping C, Sigurgeirsdottir J, Jonasson J, Eiriksdottir G, Johannsdottir J, Egilsson V, et al. Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer. Br J Cancer. 1999;81:1103-10 pubmed
- Gomez S, del Mont Llosas M, Verdu J, Roura S, Lloreta J, Fabre M, et al. Independent regulation of adherens and tight junctions by tyrosine phosphorylation in Caco-2 cells. Biochim Biophys Acta. 1999;1452:121-32 pubmed
- Burke J, Cao F, Irving P, Skumatz C. Expression of E-cadherin by human retinal pigment epithelium: delayed expression in vitro. Invest Ophthalmol Vis Sci. 1999;40:2963-70 pubmed
- Peralta Soler A, Knudsen K, Salazar H, Han A, Keshgegian A. P-cadherin expression in breast carcinoma indicates poor survival. Cancer. 1999;86:1263-72 pubmed
- Peltonen S, Hentula M, Hagg P, Ylä Outinen H, Tuukkanen J, Lakkakorpi J, et al. A novel component of epidermal cell-matrix and cell-cell contacts: transmembrane protein type XIII collagen. J Invest Dermatol. 1999;113:635-42 pubmed
- Tran N, Nagle R, Cress A, Heimark R. N-Cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion withStromal cells. Am J Pathol. 1999;155:787-98 pubmed
- Blok P, Craanen M, Dekker W, Tytgat G. Loss of E-cadherin expression in early gastric cancer. Histopathology. 1999;34:410-5 pubmed
- Wong A, Maines Bandiera S, Rosen B, Wheelock M, Johnson K, Leung P, et al. Constitutive and conditional cadherin expression in cultured human ovarian surface epithelium: influence of family history of ovarian cancer. Int J Cancer. 1999;81:180-8 pubmed
- Day M, Zhao X, Vallorosi C, Putzi M, Powell C, Lin C, et al. E-cadherin mediates aggregation-dependent survival of prostate and mammary epithelial cells through the retinoblastoma cell cycle control pathway. J Biol Chem. 1999;274:9656-64 pubmed
- Montonen O, Ezer S, Laurikkala J, Karjalainen Lindsberg M, Thesleff I, Kere J, et al. Expression of the anhidrotic ectodermal dysplasia gene is reduced in skin cancer coinciding with reduced E-cadherin. Exp Dermatol. 1998;7:168-74 pubmed
- Sancho E, Vila M, Sanchez Pulido L, Lozano J, Paciucci R, Nadal M, et al. Role of UEV-1, an inactive variant of the E2 ubiquitin-conjugating enzymes, in in vitro differentiation and cell cycle behavior of HT-29-M6 intestinal mucosecretory cells. Mol Cell Biol. 1998;18:576-89 pubmed
- Laihia J, Jansen C. Up-regulation of human epidermal Langerhans' cell B7-1 and B7-2 co-stimulatory molecules in vivo by solar-simulating irradiation. Eur J Immunol. 1997;27:984-9 pubmed
- Songun I, van de Velde C, Hermans J, Pals S, Verspaget H, Vis A, et al. Expression of oncoproteins and the amount of eosinophilic and lymphocytic infiltrates can be used as prognostic factors in gastric cancer. Dutch Gastric Cancer Group (DGCG). Br J Cancer. 1996;74:1783-8 pubmed
- Cheng L, Nagabhushan M, Pretlow T, Amini S, Pretlow T. Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol. 1996;148:1375-80 pubmed
- Rokhlin O, Cohen M. Expression of cellular adhesion molecules on human prostate tumor cell lines. Prostate. 1995;26:205-12 pubmed
contribute
- If you are aware of any publication with knockout studies validating a monoclonal or recombinant antibody, either purchased from a supplier or developed by the author(s), please notify us through feedback.
questions and comments